Welcome to our dedicated page for CervoMed SEC filings (Ticker: CRVO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CervoMed's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CervoMed's regulatory disclosures and financial reporting.
CervoMed Inc. furnished an update that investor presentation materials about its business, clinical studies, development plans and financial position are available on its website under the Investors – Events and Presentations section. The company notes these materials may be used in meetings with investors, analysts and others.
The information is provided under Regulation FD as furnished, not filed, meaning it is not subject to certain Exchange Act liabilities and is not automatically incorporated into other SEC filings unless specifically referenced.
CervoMed Inc. director Frank Zavrl received a grant of stock options as part of his non-employee director compensation. On June 8, 2026, he was awarded options to purchase 8,150 shares of common stock at an exercise price of $2.91 per share under the 2025 Equity Incentive Plan. These options vest monthly in substantially equal 1/12th increments over one year beginning June 30, 2026, contingent on his continued board service. Following this grant, Zavrl holds 8,150 stock options directly.
CervoMed Inc. director Marwan Sabbagh reported receiving a grant of stock options as part of his board compensation. On June 8, 2026, he was awarded options to purchase 8,150 shares of CervoMed common stock at an exercise price of $2.91 per share. These options were granted under the company’s 2025 Equity Incentive Plan in line with its non-employee director compensation policy. The options vest in substantially equal monthly installments over one year, with 1/12 of the underlying shares vesting on the last day of each month beginning June 30, 2026, contingent on his continued board service.
CervoMed Inc. director David Quigley received a stock option grant as part of his compensation for joining the board. On June 8, 2026, he was awarded options to buy 8,150 shares of CervoMed common stock at an exercise price of $2.91 per share, expiring on June 8, 2036.
The grant was made under the company’s 2025 Equity Incentive Plan and its non-employee director compensation policy. The underlying shares vest in substantially equal 1/12 monthly installments over one year, starting June 30, 2026, subject to his continued board service.
CervoMed Inc. reported that director Jeffrey V. Poulton received a stock option award tied to his election to the board. On June 8, 2026, he was granted options to purchase 8,150 shares of CervoMed common stock at an exercise price of $2.91 per share.
The award was granted under CervoMed’s 2025 Equity Incentive Plan pursuant to its non-employee director compensation policy. The underlying shares vest in substantially equal monthly installments over one year, with 1/12 of the award vesting on the last day of each month beginning on June 30, 2026, subject to his continued service.
CervoMed Inc. director Jane H. Hollingsworth received a stock option grant tied to her election to the board. The award covers 8,150 shares of CervoMed common stock with an exercise price of $2.91 per share and expires on June 8, 2036.
The option was granted under CervoMed’s 2025 Equity Incentive Plan in line with its non-employee director compensation policy. The underlying shares vest monthly over one year in substantially equal 1/12th increments on the last day of each month beginning on June 30, 2026, contingent on continued board service.
CervoMed Inc. director and 10% owner Sylvie Gregoire received a stock option grant related to her election to the board. The award covers 8,150 shares of common stock at an exercise price of $2.91 per share and expires on June 8, 2036. The option was granted under CervoMed’s 2025 Equity Incentive Plan in line with its non-employee director compensation policy. The underlying shares will vest in 12 equal monthly installments on the last day of each month starting June 30, 2026, contingent on her continued board service.
CervoMed Inc. director and 10% owner Joshua S. Boger received a stock option grant in connection with his election to the board. The award covers 8,150 shares of common stock at an exercise price of $2.91 per share, expiring on June 8, 2036. These shares vest in substantially equal monthly installments over one year starting on June 30, 2026, conditioned on his continued board service.
CervoMed Inc. reported an insider equity award linked to its CEO and President, John J. Alam. The Form 4 shows a grant of stock options covering 8,150 shares of common stock at an exercise price of $2.91 per share, held indirectly through his spouse.
The options were granted to Dr. Sylvie Gregoire, a non-employee director and spouse of the reporting person. The filing states that Alam disclaims beneficial ownership of these securities. The underlying shares vest monthly over one year in substantially equal 1/12 increments, beginning on June 30, 2026, subject to Dr. Gregoire’s continued service.
CervoMed Inc. entered into a securities purchase agreement for a private placement of 3,360,377 units, each consisting of common stock or a pre-funded warrant plus Series B and Series C warrants, at $3.14 or $3.139 per unit, for anticipated gross proceeds of about $10.5 million.
The financing, which includes substantial participation from company insiders and institutional healthcare investors, could generate up to an additional $21.7 million if the Series B and Series C warrants are fully exercised for cash. CervoMed plans to use the funds to advance its lead drug neflamapimod and general corporate needs, and expects its cash runway, together with existing cash, to extend into the second quarter of 2027 while it pursues a strategic partnership to move neflamapimod into Phase 3 for dementia with Lewy bodies.